Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Reich

Showing results (151-160 of 218) with videos related to

Pageof 22
Sort By:
The British Journal of Dermatology|April 29, 2021
Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy studyA B Gottlieb, J F Merola, K Reich, et al.
Archives of Dermatological Research|June 11, 2013
Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis--a multinational cross-sectional studyA Nast, U Mrowietz, K Kragballe, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 22, 2017
Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)A Menter, R B Warren, R G Langley, et al.
The British Journal of Dermatology|July 12, 2020
Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2)K B Gordon, R B Warren, A B Gottlieb, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 3, 2022
Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearanceK Reich, K B Gordon, B Strober, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 5, 2020
A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL)J Seneschal, J-P Lacour, A Bewley, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 22, 2018
Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensusU Mrowietz, J Barker, W-H Boehncke, et al.
The British Journal of Dermatology|May 26, 2017
Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III studyK Reich, A Pinter, J P Lacour, et al.
The British Journal of Dermatology|April 12, 2019
Continued treatment with secukinumab is associated with high retention or regain of responseM Augustin, D Thaci, K Eyerich, et al.
Arthritis Research & Therapy|May 4, 2019
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance dataA Deodhar, P J Mease, I B McInnes, et al.
Pageof 22

Showing results (151-160 of 218) with videos related to

Sort By:
Pageof 22
The British Journal of Dermatology|April 29, 2021
Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy studyA B Gottlieb, J F Merola, K Reich, et al.
Archives of Dermatological Research|June 11, 2013
Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis--a multinational cross-sectional studyA Nast, U Mrowietz, K Kragballe, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 22, 2017
Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)A Menter, R B Warren, R G Langley, et al.
The British Journal of Dermatology|July 12, 2020
Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2)K B Gordon, R B Warren, A B Gottlieb, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 3, 2022
Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearanceK Reich, K B Gordon, B Strober, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 5, 2020
A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL)J Seneschal, J-P Lacour, A Bewley, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 22, 2018
Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensusU Mrowietz, J Barker, W-H Boehncke, et al.
The British Journal of Dermatology|May 26, 2017
Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III studyK Reich, A Pinter, J P Lacour, et al.
The British Journal of Dermatology|April 12, 2019
Continued treatment with secukinumab is associated with high retention or regain of responseM Augustin, D Thaci, K Eyerich, et al.
Arthritis Research & Therapy|May 4, 2019
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance dataA Deodhar, P J Mease, I B McInnes, et al.
Pageof 22